Numis issued a report on Hvivo Plc (LON:HVO), upping its target price to 210.00GBX today
- Updated: September 21, 2016
Hvivo Plc (LON:HVO) had its price target raised to 210.00GBX by Numis in a report announced Thursday September 22, 2016. The bumped up stock price target indicates a possible upside of 0.18% from the company's previous stock price.
Boasting a price of 177.50GBX, Hvivo Plc (LON:HVO) traded -1.64% lower on the day. With the last stock price close down -6.27% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Hvivo Plc has recorded a 50-day average of 180.66GBX and a two hundred day average of 186.26GBX. Volume of trade was down over the average, with 5,864 shares of HVO changing hands under the typical 29,315
See Chart Below
Hvivo Plc has a 52 week low of 167.00GBX and a 52 week high of 306.50GBX Hvivo Plc’s market capitalization is currently 0 GBX.
Brief Synopsis On Hvivo Plc (LON:HVO)
hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.